March 19th, 2020 | 11:25 CET
BioNTech, Gilead, Memphasys - modern science and COVID and IVF
Table of contents:
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Development of a vaccine
The German biotech company BioNTech is working with renowned partners in China, Europe and the USA to develop a vaccine for the immunization and prevention of COVID-19 infections. A clinical trial is scheduled to start as early as April 2020. The company is pursuing the goal of making a vaccine available worldwide as quickly as possible. For this reason, BioNTech says it is "in close contact with various regulatory and scientific authorities around the world and is in ongoing discussions with other research institutions."
Investigational compound for corona viruses
US company Gilead Science is also working with global health authorities to counteract the outbreak of the new type of COVID-19 by using the investigational compound Remdesivir. Remdesivir has shown activity against MERS and SARS in animal studies, which are also corona viruses and show structural similarities to COVID-19. Since it is an experimental drug that has only been used in a small number of patients with COVID-19, Gilead is still in the early stages of development with Remdesivir.
Multi-billion growth market IVF
The Australian company Memphasys focuses on the in vitro fertilisation (IVF) market for humans, which, according to Allied Market Research, currently has a global volume of USD 13.7 billion and is expected to grow to USD 26.4 billion by 2026. Memphasys focuses on the key element of a successful pregnancy for parents who want to have children: the quality of the used sperm. Sperm quality is declining worldwide, with one in three men over the age of 40 having problems with sperm fertility. About half of all infertility cases have poor sperm as an identifying factor.
Separation of sperm
Memphasys has developed an innovative device to separate and select sperm more quickly and effectively than current methods. The device called FELIX uses electric fields and membranes to sort the sperm according to quality and size. According to Alison Coutts, CEO of Memphasys, the better sperm has a greater net negative charge compared with faulty specimens.
Launching in Q3 2020
The company's next step is to support physicians in less regulated markets so that they can use the device commercially after completion of verification and validation, which is expected in mid 2020. At the same time, the company is working to obtain marketing approval from key regulatory authorities in Australia, the United States and Europe. While approval is a multi-year and costly process, Memphasys plans to sell early in countries with lighter regulation. These initial markets could include Japan, India, New Zealand and Canada.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.